

Assessment of neurocognitive impairment in HIVinfected individuals over 50 years of age.



DJ Hughes¹, TJ Barber², A Holyome¹, D Ratcliffe², A Margetts², B Patterson², J Catalan², E Williams², A Pozniak², S Mandalia², D Asboe², M Boffito² ¹Imperial College London, ²St. Stephen's Centre, Chelsea and Westminster Hospital, London UK.


INTRODUCTION

With an ageing HIV population, co-morbidities, possible HIV-associated neurocognitive disorders (HAND) and social issues contribute to increased anxiety and depression.

- Successful cART has lead to: 1) increased life expectancy¹; and 2) increased non-HIVassociated comorbidities².
- Depression is under-diagnosed³ and associated with HAND in older HIV-infected individuals⁴.

CLINIC PATHWAY

The flowchart below illustrates the clinic pathway with regards to HAND and its referral outcome.



As part of our clinical service dedicated to those aged over 50 years, we perform formal psychological and neurocognitive assessments to assess symptomatic individuals and optimise referral pathways.

METHODS

Our clinical routine HAND assessment involves:

- 1. screening for anxiety using GAD7 questionnaire
- 2. screening for depression using PHQ9 questionnaire

AND in response to patient concerns on memory, attention, cognition and function, we also perform:

- a) Everyday Memory Questionnaire-Revised (EMQ), a subjective measure of memory failure in everyday life; and
- b) International HIV Dementia Scale (IHDS) questionnaire.

GAD7 is a patient-completed questionnaire used to screen for generalised anxiety disorder, with reliable and accurate outcomes⁵. The individual scores 7 anxiety-related symptoms from 0-3, with an overall score \geq 10 being abnormal.

RESULTS

Of the 176 patients who attended the OVER50 HIV clinic within 2 years, results were as follows:

	GAD7	PHQ9	EMQ	IHDS
Interpretable:	55	56	40	62
Abnormal result (%):	13 (24)	17 (30)	11 (28)	15 (24)

PHQ9 is also a patient-completed questionnaire used to screen for depression⁶. Each of the nine DSM-IV criteria for depression are scored from 0 (not at all) – 3 (nearly every day) with a score \geq 10 being considered abnormal.

EMQ is a shorter version of EMQ-28 with proven validity as a subjective measure of memory failure in everyday life⁷. It assesses retrieval (R) and attention (A) through patient-scoring of 13 symptoms. A total mean score of \geq 2.07 is considered abnormal.

IHDS questionnaire screens for HIV-associated dementia by evaluation of subcortical brain function. A score of ≤ 10 is considered abnormal with 80% sensitivity for diagnosing dementia⁸.

The patient is referred to psychology in response to an abnormal result, or for full neuropsychometric testing if <u>both</u> IHDS and EMQ are abnormal.

We evaluated the service and performed a univariate and multivariate logistic regression analysis (SAS version 9.1) to identify factors associated with high GAD7/PHQ9 and low EMQ/IHDS scores. These included: age, gender, ethnicity, HIV infection duration, nadir and current CD4 counts, and duration of cART treatment. Median (range) age was 59 (50-84). Median (range) nadir CD4 count was 148 (61-236), current CD4 count was 557 (391-728), and duration of cART was 164 (97-228) months.

13 of 55 and 17 of 56 had a GAD7 score \geq 10 and a PHQ9 score \geq 10 respectively and were subsequently referred to psychology.

11 of 40 had an impaired EMQ score \geq 2.07 and 15 of 62 patients had an IHDS score \leq 10.

No significant associations were found for any of the studied factors on HAND assessment results. However:

- having an abnormal GAD7 score was associated with having an abnormal PHQ9 score (p = 0.038), and
- there was a trend towards having an abnormal PHQ9 score associated with a low IHDS score (p = 0.085).

REFERENCES

- 1. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. *Lancet* 2008;**372(9635)**:293-9.
- 2. Hasse B, Ledergerber B, Furrer H et al. Morbidity and Aging in HIV-infected Persons: The Swiss HIV Cohort Study. Clin Infect Dis 2011; in press.
- 3. Rodkjaer L, Laursen T, Balle N, Sodemann M. Depression in patients with HIV is under-diagnosed: a cross-sectional study in Denmark. *HIV Med* **2011;11(1)**:46-53.
- 4. Malaspina L, Woods SP, Moore DJ *et al.* Successful cognitive aging in persons living with HIV infection. *J Neurovirol* 2011;**17(1)**:110-119.
- 5. Spitzer RL, Kroenke K, Williams JB et al. A brief measure for assessing generalised anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092-7.
- 6. Kroenke K, Spitzer RL. The PHQ-9: A new depression and diagnostic severity measure. *Psychiatric Annals* 2002;**32**:509-521.
- 7. Royle J, Lincoln NB. The Everyday Memory Questionnaire-revised: development of a 13-item scale. *Disabil Rehabil* 2008;**30(2)**:114-21.
- 8. Sacktor NC, Wong M, Nakasujja N *et al.* The International HIV Dementia Scale: a new rapid screening test for HIV dementia. *AIDS* 2005;**19**:1367-1374.

Chelsea and Westminster Hospital **MHS** Foundation Trust

CONCLUSIONS

1) Assessment for neurocognitive impairment in HIV-infected individuals over 50 years of age has been shown to be useful in its diagnosis and enhancing referral outcome.

2) HIV-infected individuals are more likely to suffer with depression in the presence of anxiety.

Exclusion of anxiety and depression when testing for HAND in patients over 50 years is important, as mental slowing, memory loss and motor disorders are common manifestations. To confirm these findings, larger cohort studies are warranted.